Promega Signs Agreement with the Guangzhou Institute of Biomedicine and Health
News Apr 11, 2007
The agreement is designed to co-develop compound profiling solutions for small molecule and traditional Chinese medicine drug screening.
By combing the drug discovery expertise of GIBH with the biological assay expertise of Promega, the partnership is intended to deliver turnkey services to pharmaceutical companies interested in speeding up their lead discovery and lead optimization processes.
GIBH scientists will offer contract services designed to profile the biology of potential leads using the Promega suite of biological drug screening assays. Initial plans call for development of Cytochrome P450, Cytotoxicity, Kinase and GPCR profiling assays.
GIBH will use the assays both in house for own discovery programs as well as offer them on a contract basis to outside companies.
International Conference on Clinical Trials & Pharmacovigilance
Feb 28 - Mar 01, 2019